(R)-4-Methyloxazolidin-2-one → (R)-3-{6-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-3-yl}-4-methyloxazolidin-2-one

HRID 1803972

반응식

HRID 1803972 반응식
Br[C:2]1[CH:3]=[CH:4][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([C:16](=[O:24])[C:17]3[CH:22]=[CH:21][C:20]([Cl:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[N:6][CH:7]=1.[CH3:25][C@@H:26]1[CH2:30][O:29][C:28](=[O:31])[NH:27]1>>[Cl:23][C:20]1[CH:21]=[CH:22][C:17]([C:16]([CH:13]2[CH2:14][CH2:15][N:10]([C:8]([C:5]3[N:6]=[CH:7][C:2]([N:27]4[C@H:26]([CH3:25])[CH2:30][O:29][C:28]4=[O:31])=[CH:3][CH:4]=3)=[O:9])[CH2:11][CH2:12]2)=[O:24])=[CH:18][CH:19]=1

참가 물질

3

반응물 2

HCID 2734858(R)-4-Methyloxazolidin-2-oneHCID 58484577(5-Bromopyridin-2-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone

생성물 1

HCID 54755119(R)-3-{6-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-3-yl}-4-methyloxazolidin-2-one수율 83.4%

실험 절차

By reaction and treatment in the same manner as in Preparation Example 31 and using (5-bromopyridin-2-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone (2.4 g) described in Preparation Example 35 and (R)-4-methyloxazolidin-2-one (728 mg) described in Preparation Example 25, the title compound (2.1 g) was obtained.

후처리

  1. customBy reaction and treatment in the same manner
  2. customas in Preparation Example 31
  3. customdescribed in Preparation Example 25

출처 및 근거

ORD 기록
ord-5dc47467ef784151ab188b492d73ec0b
출처 데이터셋
uspto-grants-2013_01
특허 번호
US08354401B2

연결된 노트

불러오는 중…